Skin Hypopigmentation in a Patient with Papillary Carcinoma Thyroid Treated with Sorafenib
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2015, Vol 2, Issue 2
Abstract
Sorafenib is an oral multikinase inhibitor approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. The dermatological side effects of sorafenib include palmar-plantar erythrodysesthesia, alopecia, skin rash, pruritus, xeroderma and erythema. Here we report a case of skin hypopigmentation related to sorafenib therapy.
Authors and Affiliations
Keechilat Pavithran
Keywords
Related Articles
- EP ID EP552007
- DOI 10.17140/CSMMOJ-2-110
- Views 116
- Downloads 0
Prostate Cancer Trends in Developing Countries
Prostate cancer is the commonest cancer in USA and most European Countries and is the 2nd commonest cancer among males globally. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, account...
Boosting Response: The Impact of Immune Checkpoint Inhibitors on Radiation Treatment Schedules
The recent FDA approvals of immunomodulatory drugs such as Nivoluvamab (Opdivo), Pembrolizumab (Keytruda) and Ipilimumab (Yervoy) for treatment of Non-small cell lung cancer (NSCLC) and melanoma have renewed interest in...
Bilateral Symmetric Thalamic Metastasis in a Patient with Small Cell Lung Cancer
A 68-year old woman was referred to our hospital because of dry cough with persistent numbness in the extremities. Chest roentgenogram showed right hilar tumor with mediastinal lymphnode and brain magnetic resonance imag...
A Rare Case of a Urachal Mucinous Cystic Tumour of Low Malignant Potential
A persistently patent urachal remnant can lead to neoplastic transformation. Urachal tumours occur most commonly as glandular neoplasms which are classified as benign, non-cystic or cystic. However, the literature on cys...
How Target Therapy can Induce Cardiotoxicity: The Onco-Cardiologist Point of View
The life expectancy of an oncological patient has been increased significantly decades due to the evolution of cancer therapies. The aim of this paper is to review how these new target molecules, which have a direct impa...